Latest Episodes
Tackling mPDAC: chemotherapy strategies that matter
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually...
Understanding Rare NSCLC Mutations: Insights, access and support
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague,...
The HER2 diagnostic and treatment landscape in NSCLC
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment...
The HER2 Diagnostic and Treatment Landscape in NSCLC
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic...
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase...
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer
This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr Roberto Salgado...